However, the Thrlog mutation increased TTR's affinity for Tq, Triac (triiodothyroacetic acid), and T, to a greater extent than it did for Tetrac (tetraiodothyroacetic acid), EMD21388 (3',5'-dibromo-4',6'-dihydroxy-3-methylflavone), and dextro-T4. These data demonstrate that a subtle change in the structure of the TI-binding channel in TTR differentially alters the affinity of binding of various iodothyronines and suggests that site-directed mutagenesis of residues within the binding channel might clarify the relative importance of specific domains of this binding channel. (Endocrinology 134: 27-34,1994) A LARGE number of point mutations in transthyretin (TTR) are associated with human disease (1). Most of these mutations alter TTR tetramer interaction and promote amyloid fibril formation and the clinical syndromes of familial amyloidotic polyneuropathy (FAP) (1). The heterozygous substitution of adenine for guanine at the first basepair of codon 109 results in a threonine for alanine substitution at amino acid 109 of the TTR monomer that increases the affinity of TTR for T4 and results in euthyroid hyperthyroxinemia in affected individuals (2,3). We previously described the clinical presentation and inheritance pattern of eight members of a single kindred expressing this mutation (3).
tetramer (4). We previously demonstrated that recombinant wild-type TTR self-associates into tetramers and has a T4-binding affinity equivalent to that of wild-type TTR purified from human plasma (5). For these studies we used both heterozygous Thr lo9-TTR purified from plasma and homozygous wild-type and Thr"' -TTRs expressed recombinantly in Escherichia coli, as described previously (5).
Materials
The current study was undertaken to better understand the molecular conformation of Thrlo9-TTR as it relates to T4 binding. We used a series of well characterized iodothyronines and a bromoflavone differing in structure from Tq to probe the interaction of Thr"' with various structural components of these iodothyronines. Our hypothesis was that differences in the affinity of different iodothyronines for Thrlo9-TTR from the affinity of these same iodothyronines for normal TTR might provide new insight into structural aspects of the T4-binding pocket in the interior of the TTR 
Results
In a separate report we demonstrated that the same preparation of wild-type TTR expressed recombinantly in E. coli that we used in these studies spontaneously associates into tetramers and binds [lz51]T4 similarly to wild-type TTR purified from plasma. At a given concentration of TTR, Thr"'-TTR bound more [lz51]Tq than wild-type TTR. Heterozygous Thrlo9-TTR purified from human plasma and homozygous recombinant Thr"' -TTR were similar in their ability to bind [1251]Tq, and both bound more T4 per pg protein than did wild-type TTR (5).
To compare more completely recombinant Thrlo9-TTR to heterozygous plasma-purified Thrlo9-TTR, we tested the ability of increasing concentrations of unlabeled T4 to compete for [1251]Tq binding to a given concentration of TTR (Fig. 1) . It should be noted that the concentration of wild-type TTR was 4 pg/ml compared to 1.5 pg/ml for both homozygous and heterozygous preparations of Thrlo9-TTR to give equivalent [1251]T4 binding. Both of these concentrations were on the linear part of the protein dose-response curves for [125I] T, binding (5). Different concentrations of these two purified TTRs were used to minimize experimental error due to low binding of T4 to wild-type TTR at concentrations that produced optimal binding for recombinant Thrlo9-TTR. The curves for both purified heterozygous Thrlo9-TTR and recombinant homozygous Thr"' were shifted to the left compared with the curve for wild-type TTR, indicating that Thr"'-TTRs had a higher affinity for T4 than wild-type TTR. Scatchard analysis of these competitive binding curves (Fig. 1 , right panel) revealed the affinities (K,s) of the homozygous and the heterozygous Thr"' -TTRs for T4 to be significantly higher (P < 0.005) than the affinity of the wild-type TTR. The competitive binding curve of recombinantly expressed homozygous Thr"' -TTR was shifted slightly further to the left than that of the heterozygous Thrlo9-TTR (Fig. l) , suggesting that the affinity for T4 of homozygous Thrro9-TTR was higher than that of heterozygous Thrlo9-TTR. Although this trend was maintained in each of the three assays, it was not statistically significant. This observation also was consistent with small differences in [1251]T4 binding by these two forms of Thrlo9-TTR, as determined in the protein dose-response studies we have reported previously (5).
We next turned our attention to the interaction of various iodothyronines with recombinant homozygous Thrlo9-TTR and recombinant wild-type TTR (Figs. 2-4) . We first compared the relative affinities of mutant and wild-type TTR for Tetrac, an iodothyronine that has the same phenolic ring structure as T4, but a different side-chain. As predicted from previous reports (1 l), Tetrac binds to wild-type TTR with higher affinity than Tq. This is demonstrated by the shift of the Tetrac dose-response curve to the left compared to the T4 dose-response curve (Fig. 2, upper panel) . When Tetrac was compared with T4 for its ability to compete for the binding of ['251]T4 to Thr"' -TTR (Fig. 2, lower panel) , the dose-response curves were nearly superimposable. At low concentrations of unlabeled ligand, the dose-response curves for T4 and Tetrac were superimposable, whereas at higher ligand concentrations (~10 nM The affinity constants computed from the slope of the Scatchard plot are 9.0 x lo', 3.7 X lo', and 8.8 X 10' for wild-type, heterozygous Thriog, and homozygous Thriog, respectively. K. values for both heterozygous and homozygous ThP are significantly different from that for WT, but not significantly different from each other. Bmax, Binding capacity (in this and following figures). binding more potently than did T4 itself, i.e. the slope of the dose-response curve for Tetrac was steeper than that for Tq. This pattern was consistent in all assays.
T3 has an affinity for TTR 2-3 orders of magnitude lower than the affinity of T4 for TTR (12). Triac has an affinity intermediate between those of T4 and T3 (12). To determine the relative importance of the phenolic iodines VS. the iodothyronine side-chain in the interactions with Thrlo9-TTR, we next assessed the relative abilities of TJ, Triac, and T4 to compete for ['251 ]Tq binding to normal and mutant recombinant TTR (Fig. 3) . T4 is a more potent competitor for [lz51]Tq binding to both wild-type TTR (Fig. 3, upper panel) and Thrio9-TTR (Fig. 3, lower panel) than either Triac or TJ. Triac is more potent than T3 in competing for T, binding to both wild-type TTR and Thr lo9-TTR. Lower concentrations of each of these ligands competed more effectively for [lz51]Tq binding to Thrlo9-TTR than to wild-type TTR (EDso for Thr"': Tq, 4 nM; Triac, 80 nM; T3, 1200 nM; EDso for wild-type TTR: Td, 35 nM; Triac, 200 nM; TJ, 4000 nM). The ratio of Triac/T, EDso values was approximately the same for these two TTRs. On the other hand, the ratio of Triac/TI EDso values was higher for binding to Thr"' -TTR than for that to wild-type TTR. This suggests that the Thrlo9-TTR mutation increased TTR's affinity for T4 slightly more than it increased its affinity for Triac or T3.
D-T, is a stereoisomer of T4 with decreased affinity for TTR (12). The bromoflavone compound EMD21388 binds to wildtype TTR with high affinity, although its orientation in the TTR T1-binding channel is different from the orientation of T4 (13). EMD21388 appears to bind in two distinct orientations within the binding channel of TTR, with its 4'-OH lying close to two Lys15 residues near the mouth of the binding channel, and its bromophenolic ring lying near the center of the binding channel, where it interacts with Ser117 (13). We compared the abilities of these compounds to compete for [lz51]T4 binding to wild-type TTR and Thr'O'-TTRs. We confirmed that L-T~ bound to TTR with higher affinity than D-T~ (Fig. 4) . In the case of wild-type TTR, the affinity of L-T~ was approximately lo-fold higher than that of D-T~ (Fig. 4, upper panel) . In the case of Thrlo9-TTR, the affinity of L-T( was loo-fold higher than that of D-T,.
EMD21388 demonstrated a binding pattern to both wild- type TTR and Thrlog-TTR similar to that of Tetrac and distinctly different from that of D-T~ (Fig. 4) . EMD21388 was 5 times more potent than T4 in competing for binding of [lz51] T4 to wild-type TTR (Fig. 4, upper panel) . On the other hand, there were no significant differences in the relative affinities of T4 and EMD21388 for Thr"'-TTR (Fig. 4, lower panel) . Similar to Tetrac, Thr"' -TTR had a slightly higher affinity for T, at lower ligand concentrations and a slightly lower affinity at higher (>lO nM) ligand concentrations. Table 1 lists the mean calculated affinities of the two TTR preparations for each of the unlabeled iodothyronines tested. Thr"'-TTR had a higher affinity for all iodothyronines tested than did wild-type TTR. As noted above, the degree to which affinity was increased by the Thr"' mutation varied among the different iodothyronines. The Thr"' mutation increased TTR's affinity for Tq by &J-fold; for T3 by 5-fold; for Triac, The concentrations of TTR used in this assay were 1.5 pg/ml for ThP-TTR and 4 pg/ml for wild-type TTR.
Tetrac, and EMD21388 by 3-fold; and for D-T~ by less than 2-fold (Table 1) . We also have expressed the differences in competition for ["'I]T4 binding as the ratio of the K, of each iodothyronine to the K, of T4 for wild-type TTR and Thr"'-TTR, respectively ( Table 2 ). The K, of iodothyronine/K, of T4 ratio was significantly higher for wild-type TTR than for Thr"'-TTR with EMD21388, Tetrac, and D-Tq. The K, of iodothyronine/K, of T4 ratio was slightly higher for wild-type than for Thr"'-TTR with T3 and Triac, but did not achieve statistical significance. Thus, the Thr"' mutation shifts the dose-response curves for all of the iodothyronines tested to the left, but its effect on Tq affinity is greater than that on the other iodothyronines tested. Other than T4, the iodothyronine affinity next most affected by the Thr"' mutation was T3, followed by Triac, EMD21388, and Tetrac. The affinity least affected by the mutation was that of D-T,.
Discussion
An adenine for guanine substitution in exon 4 of the TTR gene that changes amino acid 109 from alanine to threonine increases the affinity of TTR for T4 and causes euthyroid hyperthyroxinemia. TTR isolated from the plasma of a patient heterozygous for this point mutation has an affinity for T4 approximately 3-fold higher than that of wild-type TTR (3). Although much is known about the three-dimensional structure of TTR and its interaction with Tl, little is known about how specific mutations in the TTR monomer might alter the binding of T4 and other iodothyronines to TTR. The availability of recombinantly expressed wild-type TTR and Thr"' human TTR has allowed us to explore these interactions.
The findings reported here and previously (3, 5, 9) unequivocally demonstrate that substitution of threonine for alanine at position 109 of the TTR monomer increases the affinity of the homozygous recombinant TTR tetramer for Tq. We predicted that the homozygous Thrlo9-TTR would bind with an affinity greater than that of the heterozygous Thrlo9-TTR, because some point mutations in TTR that lower the affinity for Tq (Ile"', Met3', and His58) have a greater effect when homozygous than when heterozygous (5, 9). In fact, despite the fact that there was a trend for the homozygous form of the Thr"' mutation to have higher affinity than the heterozygous form purified from plasma, we could not demonstrate a statistically significant difference in Tq affinity between these two forms. One possible explanation for the similarity in T4 binding affinity between the homozygous recombinant TTR and the heterozygous form purified from plasma is that approximately 50% of all monomers translated in the heterozygote should be Thr"', and half should be wild type. This theory is supported by amino acid sequencing data of the heterozygous protein purified from the plasma of an affected family member (3). If wild-type and Thr"' monomers associate into tetramers randomly (14, 15), then one would expect that 93.75% [l-(l/~)~] of all the tetramers would have at least one Thr"' monomer. It is possible that the phenotype for increased T4 binding needs only one mutant monomer to be present in the TTR tetramer. This Thr"' monomer might determine the orientation of Tq within the binding channel and increase binding affinity. This could account for the absence of a significant difference between the heterozygous and homozygous Thr"'-TTRs. The data presented here are consistent with this hypothesis, but provide no specific confirmation of it.
TTR contains two potential T1-binding sites. A number of investigators have demonstrated apparent negative cooperativity between these two sites; that is, occupancy of one site lowers the affinity of the second site for T4 (16). The molecular basis for site-site interaction within the TTR tetramer is not known and cannot be predicted even from x-ray diffraction analysis. It is possible that the Thr"' mutation interferes with the site-site interaction and increases the apparent affinity of the TTR tetramer by allowing only high affinity binding in both binding sites. Although this possibility is intriguing, the Scatchard plots in Fig. 1 do not support the presence of a second high affinity binding site. We and others have reported the binding of Tq to several TTRs in which naturally occurring point mutations have been associated with human disease (9, 17). Of the large number of point mutations in TTR, most have been associated with the syndrome of familial amyloidotic polyneuropathy (1). In these syndromes, point mutations in TTR promote amyloid fibril formation by as yet unknown mechanisms. The majority of these point mutations are on the surface of the TTR monomer and do not directly involve the T,-binding channel in the center of the TTR tetramer (9, 18, 19) . In most TTR point mutations causing amyloid formation, there is little or no change in the affinity of TTR for T4, Unlike the majority of these TTRs, TTRs with a histidine substitution at position 58, a methionine substitution at position 30, or an isoleucine substitution at position 122 all have reduced affinity for T4, and this affinity is decreased more in the recombinant (and naturally occurring) homozygous forms than in the heterozygous forms found in plasma (5,9). The molecular basis for these changes remain obscure. Only the homozygous Met3' mutation has been studied by x-ray diffraction analysis. In a recently published analysis of the crystal structure of homozygous Hamilton et al. (20) demonstrated that the methionine substitution at position 30 forces the two @-sheets that constitute the T4-binding channel apart by an average of 0.4 A. These investigators also speculate that this amino acid substitution decreases the size of the distal TK binding pocket and, thus, lowers the affinity of the mutant TTR for T4 (21). Steinrauf et al. postulated that an increase in the size of the distal T4-binding channel pocket in Thr"'-TTR may determine the increased affinity of this mutant TTR for T4, but no direct evidence is provided to support this hypothesis (21).
What are the effects of altering iodine number and sidechains on the interactions of iodothyronines with Thr"'-TTR? No previous studies have evaluated the binding of various iodothyronines to recombinant human TTRs expressed in E. coli, although several studies have compared the relative affinities of different iodothyronines to TTR purified from plasma (11, 22) . The affinities for recombinant wild-type TTR of most of the iodothyronine analogs that we tested were consistent with published data, except for D-T,, which had an affinity for wild-type TTR greater than that of T3, whereas the opposite has been described previously by Andrea et al. (22) . The only major difference between the methodology used in the current study and that of Andrea et al. is that Andrea et al. used equilibrium dialysis to separate bound from free iodothyronine and we used dextran-coated charcoal. It is not clear what role the differences in separation techniques had on these findings, as we found that D-T, has a higher affinity than T3 for TTR using an anti-TTR immunoprecipitation method to separate bound from free [1251]T4. Somack et al. (ll) , using gel filtration techniques to measure the association of iodothyronines to TTR, found that TTR's affinity for D-T~ was higher than its affinity for T3, findings in agreement with those reported here.
Although crystallographic studies on TTR have mapped residues in the T1-binding channel predicted to interact with T4 (4, 13, 20, 21, (23) (24) (25) , the relative importance of each of these residues is unknown. The effects of the Thr"' mutation on T4 binding cannot be predicted easily based on the crystallographic data of Blake et al. (19, 23) , , or the more recent data of Steinrauf et al. (21) . Some controversy exists concerning the microenvironment of the Tqbinding channel in TTR. There appear to be subtle differences in the structure of the TTR-binding channel determined by Blake, in which crystals of TTR were soaked in T4 and the structure of TTR-T4 crystals generated from solutions containing both TTR and T4 was determined (27). Specifically, the presence of a water molecule found by Blake in the innermost portion of the T1-binding pocket is not present in the x-ray diffraction pattern determined on TTR crystallized in the presence of T4 (27) or other inhibitors (24-26). The absence of this water molecule alters the positions of the phenolic iodines within the binding channel. It is possible that the Thr"' mutation increases TTR's affinity for T, by facilitating the interaction between the T4 side-chain and the TTR molecule. However, using either Steinrauf's (21) or Cody's (26) data, this theory is not supported readily by the location of amino acid residue 109. Based on the x-ray crystallographic data of Blake, the effect of the threonine substitution at position 109 on T4 binding is not clear. Residue 109 is located midway along the molecule, opposite the 5'-iodine (phenolic) of T4 (4, 19, 23, 26) . Currently available data suggest that residue 109 does not project into the core of the binding site, where contact points with T4 are predicted to occur (26).
There are several possible explanations for the effects of the Thr"' mutation on TTR's affinity for Tq. It is possible that the Thr"' mutation alters the orientation of T, in the binding channel such that the interaction between Lys15 and the side-chain of T4 is facilitated. Alternatively, perhaps the hydroxyl group of the Thr"' residue introduced by this mutation is involved in a direct interaction with the T4 molecule. Another possible explanation suggested by Wojtczak et al. (26) on the basis of molecular modeling of Thrlo9-TTR and 3,3'-diiodo-L-thyronine was that the threonine for alanine substitution at position 109 shortens the distance between the T4 5'-phenolic iodine and the fragments of residues 108-110 that appear to be involved in binding this iodine moiety. Finally, based on x-ray diffraction data collected on recombinant Thrlo9-TTR crystallized in the ab-BINDING TO MUTANT TTR sence of T4, Steinrauf et al. (21) suggest that the increased affinity of this mutant TTR is the result of the increased width of the distal end (phenolic end) of the T4-binding site. By studying the binding to TTR of a number of iodothyronine analogs of T4 with varying numbers and positions of iodine moieties and different side-chains we hoped to gain additional insight into the nature of the effects of substituting threonine for alanine at position 109 of TTR. Indeed, the relative affinities of wild-type TTR and Thrlo9-TTR for various iodothyronines differ.
Tetrac and D-T~ and the bromoflavone EMD21388 do not demonstrate the same relative increase in affinity for the mutant TTR as does T,. The Thr"' mutation increases the binding of T3 (an analog that differs only by a distal phenolic iodide) to TTR almost as much as it increases the binding of T4 to TTR. If the higher affinity of Tetrac relative to T4 for wild-type TTR is determined by the interaction (and stabilization) of the acetic acid moiety of tetrac with the NH, group of LyP, then the Thr"' substitution may have less of an impact on Tetrac than on Tl, which has an NH2 group of its own in proximity to Lys". In the case of EMD21388, preliminary data suggest that its orientation within the TTR-binding channel is more stable than that of T4 and that it can occupy the T4-binding site in either of two stable orientations (13). As is the case for Tetrac, the higher affinity binding of EMD21388 compared to T4 in wild-type TTR may preclude much of the effect of the Thr"' substitution. The situation with D-T, is not clear, but probably relates to the different orientations of the side-chain with Lys" and Ser117.
The data reported here demonstrate that even a range of iodothyronine analogs used with a single conservative TTR point mutation does not completely explain the mechanism by which this naturally occurring mutation expresses an increased affinity for T4. These data do suggest that complete understanding of the effects of point mutations in TTR on T4 binding cannot be derived from either crystal structure (21) or ligand binding studies alone. Further clarification of the enhanced interaction of Thr'09-TTR with T4 may have to await x-ray crystallographic imaging of this mutant protein cocrystallized with T,. Additional information on the relative importance of other individual amino acid residues in the center of the T4-binding channel in TTR is now testable by creating site-directed mutations of these residues.
